BRKR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

958.30M

-2.17%

0.648

-14.69%

803.82M

+0.3%

0.422

-10.27%

815.12M

+2.22%

0.411

+28.29%

Estimates Revision

The market is revising Downward the revenue expectations for Bruker Corporation (BRKR) for FY2025, with the revenue forecasts being adjusted by -0.85% over the past three months. During the same period, the stock price has changed by 37.31%.

Revenue Estimates for FY2025

Revise Downward

-0.85%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.11%

In Past 3 Month

Stock Price

Go Up

+37.31%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast BRKR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 44.60 USD with a low forecast of 42.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 45.670

Low

42.00

Averages

44.60

High

50.00

Current: 45.670

Low

42.00

Averages

44.60

High

50.00

Barclays

NULL -> Overweight

maintain

$45 -> $55

2025-12-15

New

Reason

Barclays

Price Target

$45 -> $55

2025-12-15

New

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Bruker to $55 from $45 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Wells Fargo

Brandon Couillard

maintain

$48 -> $55

2025-12-15

New

Reason

Wells Fargo

Brandon Couillard

Price Target

$48 -> $55

2025-12-15

New

maintain

Reason

Wells Fargo analyst Brandon Couillard raised the firm's price target on Bruker to $55 from $48 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Wolfe Research

Doug Schenkel

Peer Perform -> Outperform

upgrade

$60

2025-12-10

Reason

Wolfe Research

Doug Schenkel

Price Target

$60

2025-12-10

upgrade

Peer Perform -> Outperform

Reason

Wolfe Research analyst Doug Schenkel upgraded Bruker to Outperform from Peer Perform with a $60 price target.

Wolfe Research

Peer Perform -> Outperform

upgrade

$60

2025-12-10

Reason

Wolfe Research

Price Target

$60

2025-12-10

upgrade

Peer Perform -> Outperform

Reason

Wolfe Research upgraded Bruker to Outperform from Peer Perform with a $60 price target. The firm cites its 2026 outlook for the upgrade, which assumes low-single-digit revenue growth, 200 basis points of margin expansion, and low- to mid-teens earnings growth for Bruker. The company's semiconductor orders shifted into the first half of 2026 from the second half of 2025, which brings good visibility with seven months of backlog, the analyst tells investors in a research note. Wolfe believes Bruker's growth and margin trajectory in 2026 will drive valuation upside.

Goldman Sachs

Sell

initiated

$40

2025-12-09

Reason

Goldman Sachs

Price Target

$40

2025-12-09

initiated

Sell

Reason

Goldman Sachs initiated coverage of Bruker with a Sell rating and $40 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.

Rothschild & Co Redburn

Buy

initiated

$60

2025-11-20

Reason

Rothschild & Co Redburn

Price Target

$60

2025-11-20

initiated

Buy

Reason

Rothschild & Co Redburn initiated coverage of Bruker with a Buy rating and $60 price target, representing 41% potential upside. Bruker has underperformed its life science equipment peers year-to-date, with revenue and margins pressured by academic and government budget cuts and tariffs, the analyst tells investors in a research note. However, the firm views the company as well positioned to return to above-market earnings growth from 2026, given its leadership in proteomics and demand for next-generation systems such as mass spectrometry.

Valuation Metrics

The current forward P/E ratio for Bruker Corp (BRKR.O) is 22.85, compared to its 5-year average forward P/E of 26.68. For a more detailed relative valuation and DCF analysis to assess Bruker Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

26.68

Current PE

22.85

Overvalued PE

33.27

Undervalued PE

20.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

17.64

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

20.99

Undervalued EV/EBITDA

14.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.31

Current PS

0.00

Overvalued PS

4.31

Undervalued PS

2.32

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 113.25% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 113.25% over the last month.

Sold

Bought

BRKR News & Events

Events Timeline

No data

News

6.0

12-10Newsfilter

Bruker Secures $25 Million in European Orders for Advanced NMR Systems

8.5

11-24Newsfilter

AST Revolution Acquired by Bruker, Advancing Rapid Antimicrobial Susceptibility Testing Technology

6.0

11-20Benzinga

Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday

People Also Watch

Frequently Asked Questions

What is Bruker Corp (BRKR) stock price today?

The current price of BRKR is 45.67 USD — it has increased 1.2 % in the last trading day.

What is Bruker Corp (BRKR)'s business?

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.

What is the price predicton of BRKR Stock?

What is Bruker Corp (BRKR)'s revenue for the last quarter?

Bruker Corp revenue for the last quarter amounts to 860.50M USD, decreased -0.45 % YoY.

What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?

Bruker Corp. EPS for the last quarter amounts to -0.41 USD, decreased -251.85 % YoY.

What changes have occurred in the market's expectations for Bruker Corp (BRKR)'s fundamentals?

How many employees does Bruker Corp (BRKR). have?

Bruker Corp (BRKR) has 11396 emplpoyees as of December 16 2025.

What is Bruker Corp (BRKR) market cap?

Today BRKR has the market capitalization of 6.94B USD.